NY-ECOVADIS
13.7.2022 09:02:11 CEST | Business Wire | Press release
EcoVadis , the leading provider of globally trusted business sustainability ratings, today announced the acquisition of ecotrek , a sustainability data mining company. The company’s automated sustainability data collection, scanning, and analysis capabilities will complement EcoVadis’ portfolio of solutions by enhancing technical capabilities, improving customer experience, and expanding visibility with robust information about trading partners, thus accelerating the pace of its global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005172/en/
With over 5 million company profiles already in its database, ecotrek’s sustainability data mining (SDM) capabilities make it possible to automate the gathering and integration of sustainability data into business processes. This gives EcoVadis unmatched access to company-specific insights to understand environmental, social and ethical risk and opportunity, providing even faster and more robust risk visibility for organizations across the entire supply chain.
“The acquisition of ecotrek strengthens our position as the optimal choice for companies to drive sustainability impact at scale across their value chains. We welcome ecotrek’s entrepreneurial team, technology and expertise into our purpose and culture,” said Pierre-François Thaler, co-CEO at EcoVadis. “This is an important step forward as we ramp up our investment in technology and sustainability intelligence capabilities that we are excited to bring to our global customer base.”
ecotrek’s SDM expands upon EcoVadis’ technical capabilities with automated data collection, scanning, analysis, and classification of a company’s sustainability information. This enables EcoVadis to provide even smarter and faster predictive intelligence to optimize sustainability risk management strategies. It also enables EcoVadis to enhance the quality and experience in its ratings while boosting process efficiency for improving the engagement journey with value chain partners. The combined product suite will provide an end-to-end offering from risk classification and monitoring to supplier sustainability performance improvement.
“We shaped and validated our technology around a deep and growing market need for easing and accelerating sustainability insights. EcoVadis is the ideal partner to advance our mission to help companies deploy sustainable procurement at a global scale,” said Rena Kleine, Co-CEO at ecotrek. "By joining forces with EcoVadis, our customers will realize huge benefits in product growth, ability to scale and enable them to integrate sustainability into their procurement processes quickly for maximum impact.”
In light of rising regulations, such as the German Supply Chain Act and the imminent European Directive on supply chain due diligence, the combined end-to-end offerings give customers a giant head start over their peers on monitoring and improving their supply chain to be not only compliant with this law, but to thrive in the new responsible business environment.
ecotrek’s four co-founders brought together their backgrounds in software, engineering, and applied science to create the company in 2020. They and their entire team will join the EcoVadis business and merge with the EcoVadis team in Germany. For more details, contact EcoVadis .
About EcoVadis
EcoVadis is a purpose-led company whose mission is to provide globally trusted business sustainability ratings. Businesses of all sizes rely on EcoVadis’ expert intelligence and evidence-based ratings to monitor and improve the sustainability performance of their business and trading partners. Its actionable scorecards, benchmarks, carbon action tools, and insights guide an improvement journey for environmental, social and ethical practices across 200 industry categories and 175 countries. Industry leaders such as Amazon, Johnson & Johnson, L’Oréal, Unilever, LVMH, Salesforce, Bridgestone, BASF and JPMorgan are among the 95,000 businesses that collaborate with EcoVadis to drive resilience, sustainable growth and positive impact worldwide. Learn more on ecovadis.com
, Twitter
or LinkedIn
.
About ecotrek
ecotrek is a sustainability data mining startup focusing on automated supplier monitoring for the entire supply chain based on publicly available data points. Through machine learning enabled data collection & classification, the ecotrek SDM technology assures instant data insights for thousands of suppliers in a few hours, leading to actionable insights and improvement of the overall supply chain sustainability. Learn more on ecotrek.tech
or LinkedIn
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005172/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
